Jeffrey L Wade's most recent trade in Lexicon Pharmaceuticals Inc was a trade of 307,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 8, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2024 | 307,000 | 307,000 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Jeffrey Wade L. | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 49,113 | 361,905 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Wade Jeffrey L. | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 49,113 | 98,227 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Wade Jeffrey L. | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 37,691 | 324,214 (0%) | 0% | 2.6 | 98,750 | Common Stock |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 37,274 | 312,792 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Wade Jeffrey L. | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 37,274 | 37,273 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey Wade L. | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 11,177 | 275,518 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | L. Jeffrey Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 11,177 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | L. Wade Jeffrey | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 314,320 | 314,320 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Wade L. Jeffrey | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 314,320 | 314,320 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Purchase of securities on an exchange or from another person at price $ 2.34 per share. | 20 Jun 2023 | 10,000 | 252,341 (0%) | 0% | 2.3 | 23,350 | Common Stock |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Purchase of securities on an exchange or from another person at price $ 2.32 per share. | 20 Jun 2023 | 2,000 | 254,341 (0%) | 0% | 2.3 | 4,650 | Common Stock |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 37,273 | 74,547 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 37,273 | 272,596 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 30,467 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 30,467 | 224,147 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 30,255 | 242,341 (0%) | 0% | 2.2 | 65,653 | Common Stock |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 11,176 | 11,177 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 11,176 | 235,323 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 442,030 | 442,030 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 147,340 | 147,340 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 30,466 | 30,467 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 30,466 | 208,276 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 25,773 | 193,680 (0%) | 0% | 2.8 | 73,453 | Common Stock |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 25,290 | 177,810 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 25,290 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 11,177 | 22,353 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 11,177 | 219,453 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 335,470 | 335,470 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 111,820 | 111,820 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 30,467 | 60,933 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 30,467 | 183,604 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.19 per share. | 28 Feb 2021 | 26,584 | 157,020 (0%) | 0% | 7.2 | 191,139 | Common Stock |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 25,290 | 25,290 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 25,290 | 153,137 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 9,555 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 9,555 | 127,847 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,797 | 118,292 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,797 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 100,600 | 100,600 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Jeffrey L. Wade | EVP, Corp Adm Affairs and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 33,530 | 33,530 | - | - | Restricted Stock Units |